PRACTICE-BASED BLOOD PRESSURE MANAGEMENT IN 1000 PATIENTS USING THE CUREAPP HT DIGITAL THERAPEUTICS FOR HYPERTENSION

Akihiro Nomura,Yusuke Takagi,Tomoyuki Tanigawa,Kazuomi Kario
DOI: https://doi.org/10.1097/01.hjh.0001019624.40710.cc
IF: 4.9
2024-05-01
Journal of Hypertension
Abstract:Objective: The HERB-DH1 randomized controlled trial recently demonstrated significant reductions in ambulatory, home, and office blood pressures in essential hypertension patients using a novel digital therapeutics (DTx) app for hypertension (CureApp HT, CureApp, Inc.) for up to six months. However, its effectiveness in clinical practice, particularly regarding the influence of patient age and concurrent antihypertensive medication use, remains underexplored. This study aims to assess blood pressure changes in the first 1000 hypertensive patients prescribed the DTx app in a practice-based real-world data (RWD) cohort. Design and method: Deidentified data from the CureApp HT clinical information database were analysed. The primary endpoint was the change in morning home SBP from baseline to week 12. Key secondary endpoints included changes in morning home SBP from baseline to week 24, and app engagement rates from baseline to week 12 and 24. We also compared home morning SBPs between the practice-based RWD cohort and the historical HERB-DH1 control group using analysis of covariance. Results: The practice-based RWD cohort (mean age, 54.8 ± 11.6 years; 48.9% female; baseline morning home SBP, 132.8 ± 12.9 mmHg; and median app engagement rate, 91.7%) showed reductions in morning home SBP of -4.9 mmHg (CI, -5.6 to -4.2) at week 12 and -6.1 mmHg (CI, -7.3 to -5.0) at week 24, both significantly larger than those in the HERB-DH1 control group. Subgroup analysis revealed pragmatic SBP reductions with DTx in patients aged equal or more than 65 years or on antihypertensive medication at baseline, populations previously excluded in the HERB-DH1 trial. Conclusions: Conclusions: Significant reductions in morning home SBP were observed in the first 1000 hypertensive patients prescribed the DTx app compared to the HERB-DH1 control group. These findings might suggest importance of the DTx app’s engagement and effectiveness that could extends to elderly patients and those on antihypertensive medication.
peripheral vascular disease
What problem does this paper attempt to address?